429 related articles for article (PubMed ID: 12917462)
1. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes.
Corbet S; Nielsen HV; Vinner L; Lauemoller S; Therrien D; Tang S; Kronborg G; Mathiesen L; Chaplin P; Brunak S; Buus S; Fomsgaard A
J Gen Virol; 2003 Sep; 84(Pt 9):2409-2421. PubMed ID: 12917462
[TBL] [Abstract][Full Text] [Related]
2. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals.
Thorn M; Tang S; Therrien D; Kløverpris H; Vinner L; Kronborg G; Gerstoft J; Corbet S; Fomsgaard A
APMIS; 2007 Jun; 115(6):757-68. PubMed ID: 17550385
[TBL] [Abstract][Full Text] [Related]
3. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.
Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD
J Immunol; 2003 Nov; 171(10):5611-23. PubMed ID: 14607970
[TBL] [Abstract][Full Text] [Related]
4. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais.
Bond KB; Sriwanthana B; Hodge TW; De Groot AS; Mastro TD; Young NL; Promadej N; Altman JD; Limpakarnjanarat K; McNicholl JM
AIDS Res Hum Retroviruses; 2001 May; 17(8):703-17. PubMed ID: 11429111
[TBL] [Abstract][Full Text] [Related]
5. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
Okazaki T; Pendleton CD; Lemonnier F; Berzofsky JA
J Immunol; 2003 Sep; 171(5):2548-55. PubMed ID: 12928405
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.
Woodberry T; Gardner J; Mateo L; Eisen D; Medveczky J; Ramshaw IA; Thomson SA; Ffrench RA; Elliott SL; Firat H; Lemonnier FA; Suhrbier A
J Virol; 1999 Jul; 73(7):5320-5. PubMed ID: 10364278
[TBL] [Abstract][Full Text] [Related]
7. Vpr is preferentially targeted by CTL during HIV-1 infection.
Altfeld M; Addo MM; Eldridge RL; Yu XG; Thomas S; Khatri A; Strick D; Phillips MN; Cohen GB; Islam SA; Kalams SA; Brander C; Goulder PJ; Rosenberg ES; Walker BD;
J Immunol; 2001 Sep; 167(5):2743-52. PubMed ID: 11509618
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection.
Addo MM; Yu XG; Rosenberg ES; Walker BD; Altfeld M
DNA Cell Biol; 2002 Sep; 21(9):671-8. PubMed ID: 12396610
[TBL] [Abstract][Full Text] [Related]
9. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif.
Altfeld MA; Livingston B; Reshamwala N; Nguyen PT; Addo MM; Shea A; Newman M; Fikes J; Sidney J; Wentworth P; Chesnut R; Eldridge RL; Rosenberg ES; Robbins GK; Brander C; Sax PE; Boswell S; Flynn T; Buchbinder S; Goulder PJ; Walker BD; Sette A; Kalams SA
J Virol; 2001 Feb; 75(3):1301-11. PubMed ID: 11152503
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
12. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
McKinney DM; Skvoretz R; Livingston BD; Wilson CC; Anders M; Chesnut RW; Sette A; Essex M; Novitsky V; Newman MJ
J Immunol; 2004 Aug; 173(3):1941-50. PubMed ID: 15265928
[TBL] [Abstract][Full Text] [Related]
13. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
Marsac D; Puaux AL; Rivière Y; Michel ML
Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.
Currier JR; deSouza M; Chanbancherd P; Bernstein W; Birx DL; Cox JH
J Virol; 2002 May; 76(10):4971-86. PubMed ID: 11967314
[TBL] [Abstract][Full Text] [Related]
15. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.
Brander C; Yang OO; Jones NG; Lee Y; Goulder P; Johnson RP; Trocha A; Colbert D; Hay C; Buchbinder S; Bergmann CC; Zweerink HJ; Wolinsky S; Blattner WA; Kalams SA; Walker BD
J Virol; 1999 Dec; 73(12):10191-8. PubMed ID: 10559335
[TBL] [Abstract][Full Text] [Related]
16. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
[TBL] [Abstract][Full Text] [Related]
17. Screening for CD8 cytotoxic T lymphocytes specific for Gag of human immunodeficiency virus type 1 subtype B' Henan isolate from China and identification of novel epitopes restricted by the HLA-A2 and HLA-A11 alleles.
Gong X; Gui X; Zhang Y; Tien P
J Gen Virol; 2006 Jan; 87(Pt 1):151-158. PubMed ID: 16361427
[TBL] [Abstract][Full Text] [Related]
18. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
19. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
Borghan MA; Oka S; Takiguchi M
Tissue Antigens; 2005 Oct; 66(4):305-13. PubMed ID: 16185326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
